Amicus Therapeutics Inc. (NASDAQ:FOLD) shares traded 3.39% higher at $11.90 on Wall Street last session.
In accordance with the data, 13 analysts cover Amicus Therapeutics Inc. (NASDAQ:FOLD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $12.00, we find $16.00. Given the previous closing price of $11.51, this indicates a potential upside of 39.01 percent. FOLD stock price is now 4.08% away from the 50-day moving average and 2.15% away from the 200-day moving average. The market capitalization of the company currently stands at $3.28B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
It has been rated a hold by 5 analysts and a buy by 8. Brokers who have rated the stock have averaged $15.82 as their price target over the next twelve months.
In other news, Crowley John F, Executive Chairman sold 6,044 shares of the company’s stock on May 15. The stock was sold for $67,577 at an average price of $11.18. Upon completion of the transaction, the Executive Chairman now directly owns 962,361 shares in the company, valued at $11.45 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01, President & CEO Campbell Bradley L sold 11,700 shares of the business’s stock. A total of $138,093 was realized by selling the stock at an average price of $11.80. This leaves the insider owning 823,454 shares of the company worth $9.8 million. Insiders disposed of 1,170,499 shares of company stock worth roughly $13.93 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FOLD stock. A new stake in Amicus Therapeutics Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $26,765,000. GREAT LAKES ADVISORS, LLC invested $6,828,000 in shares of FOLD during the first quarter. In the first quarter, GHOST TREE CAPITAL, LLC acquired a new stake in Amicus Therapeutics Inc. valued at approximately $5,653,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in FOLD for approximately $4,629,000. GREAT POINT PARTNERS I LP purchased a new stake in FOLD valued at around $4,522,000 in the second quarter. In total, there are 320 active investors with 105.77% ownership of the company’s stock.
During the past 12 months, Amicus Therapeutics Inc. has had a low of $7.22 and a high of $13.84. As of last week, the company has a debt-to-equity ratio of 3.83, a current ratio of 2.90, and a quick ratio of 2.70. The fifty day moving average price for FOLD is $11.44 and a two-hundred day moving average price translates $11.66 for the stock.
The latest earnings results from Amicus Therapeutics Inc. (NASDAQ: FOLD) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.18, missing analysts’ expectations of -$0.15 by -0.03. This compares to -$0.30 EPS in the same period last year. The net profit margin was -60.60% and return on equity was -153.70% for FOLD. The company reported revenue of $86.27 million for the quarter, compared to $78.72 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 9.6 percent. For the current quarter, analysts expect FOLD to generate $89.74M in revenue.
Amicus Therapeutics Inc.(FOLD) Company Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children’s Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Leave a Reply